Lexaria Bioscience : Corporate Highlight Sheet

LEXARIA BIOSCIENCE CORP.

NASDAQ: LEXX

INVESTOR CONTACT

Phone: [phone] ext. 202 [e-mail]

DRUG DELIVERY PLATFORM INNOVATOR

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

2024 Investment Highlights

• Hypertension: IND opening study HYPER-H23-1
• GLP-1drugs: Conduct animal and human clinical studies to examine DehydraTECH-processedGLP-1 drugs

DehydraTECH

• Patented formulation and dehydration processing method changes how the body detects and absorbs drugs
• 41 patents granted covering method-of-use,composition-of-matter and medical treatment claims



Patented DehydraTECH Process

1	Combine Active		Apply to food / carrier	Perform dehydration		Render as powder or liquid for use
	Pharmaceutical Ingredient	2	particles	3 synthesis procedure	4	in desired final form factor

with Fatty Acid Oil

DehydraTECH Benefits

Speeds up onset Increases bioavailability Improves drug potency Lower dosage Lower cost

DehydraTECH in Published Papers

For more information visit: Lexaria Research	Journal of Functional Foods - November 2023
International Journal of Molecular Sciences - June 2023	Biomedicine & Pharmacotherapy - June 2023
Advances in Therapy - June 2023	Pharmaceuticals - April 2023
Cannabis and Cannabinoid Research - April 2023	Biomedicine & Pharmacotherapy - April 2023
Journal of Personalized Medicine - June 2022	Advances in Therapy - September 2019

PRICE	52 WK RANGE	AVG. VOLUME	SHARES OUTSTANDING	MARKET CAP	INSIDER OWNERSHIP
$3.45	$0.65 - $6.85	952,633	12.9 M	$41.8 M	5.0%

Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, Canada

www.lexariabioscience.com

LEXARIA BIOSCIENCE CORP.

NASDAQ: LEXX

INVESTOR CONTACT

Phone: [phone] ext. 202 [e-mail]

DRUG DELIVERY PLATFORM INNOVATOR

DehydraTECH FDA Phase 1b IND Program - Stage 1/2 Hypertension

• Successfulpre-INDmeetingwith the FDA in 2022 with 505(b)(2)NDA regulatory pathway confirmed;
• Received FDA clearancefor IND opening study HYPER-H23-1
• Phase 1b randomized, double-blind,placebo-controlled study of the safety, pharmacokinetics, and pharmacodynamics of DehydraTECH-CBD for the treatment of stage 1 or 2 hypertension
• Only a handful ofother published studieshave investigated resting blood pressure impacts of CBD; none have reported sustained reductions except DehydraTECH-CBD
• FDA has issuedclear guidelinesdefining the need for new antihypertensives that offer novel modes of action
• Treatment of Stage 1 or 2 hypertensive patients not adequately managed with existing treatments

DehydraTECH for Diabetes and Weight Loss

• Randomized, cross-over,single-dose,Investigator-initiated pilot study in 7 healthy volunteers
• Rybelsus® 7mg tablets vs. DehydraTECH-Semaglutide 7 mg compound formulated capsules
• Blood sampled at 18 intervals from T=0 to T=600 min and again at T=24hr post-dose follow up
• Higher blood semaglutide levels / AUC demonstrated throughout the studyduration withDehydraTECH (p<0.05)
• Blood glucose levels lower throughout the study with DehydraTECH (p<0.05); most notably post prandially
• Enhancedcentral deliveryattributes of DehydraTECH contributed to the pronounced GLP-1 effect profile
• Apparent improvements in gastrointestinal tolerability witnessed: Zero instances of moderate nausea/diarrhea with DehydraTECH-Semaglutide; moderate nausea (n=2) and moderate diarrhea (n=1) only reported with Rybelsus® treatment
• Detailed overview of Lexaria's 2024 GLP-1/Diabetes and Weight Loss Study Programs

		Blood semaglutide levels					Blood glucose levels
	Rybelsus 7mg (n=7)		DehydraTECH-Semaglutide 7mg (n=7)		Rybelsus 7mg (n=7)	DehydraTECH-Semaglutide 7mg (n=7)
10.0								6.0
8.0								5.5
6.0								5.0
								4.5
4.0								4.0
2.0								3.5
0.0								3.0
0	100	200	300	400	500	600	700	0	200	400	600	800
			Time (min)						Time (min)
							MANAGEMENT

Chris Bunka, Chairman & CEO

• Launched several successful private and public companies since the late 1980's
• Extensive experience in the capital markets, corporate governance, M&A and finance
• Named inventor on multiple patent innovations

John Docherty, M.Sc., President & Director

• Specialist in development of drug delivery technologies
• Former President and COO of Helix BioPharma Corp. (TSX: HBP)
• Named inventor on multiple issued and pending patents

Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, Canada

www.lexariabioscience.com